Lonza | Jotup

Gastroretentive Drug Delivery Systems Outsourcing Market Analysis Report 2023: Increased Focus on Localized Drug Delivery - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on:

수요일, 11월 29, 2023

The "Gastroretentive Drug Delivery Systems Outsourcing Market Size, Share & Trends Analysis Report By Dosage Form (Tablets, Liquid, Microspheres, Capsule, Others), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Gastroretentive Drug Delivery Systems Outsourcing Market Size, Share & Trends Analysis Report By Dosage Form (Tablets, Liquid, Microspheres, Capsule, Others), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
The global gastroretentive drug delivery systems outsourcing market size is expected to reach USD 2.27 billion by 2030.
Furthermore, an increased focus on localized drug delivery is expected to boost market growth.
Gastroretentive drug delivery systems are indicated for localized drug delivery applications in the gastrointestinal tract.

United States Oral Solid Dosage Contract Manufacturing Research Report 2023: Market to Reach $16.42 Billion by 2030 - One-Stop-Shop Solutions Transforming the Industry - ResearchAndMarkets.com

Retrieved on:

화요일, 11월 28, 2023

Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Product Type (Tablets, Capsules), By Mechanism (Controlled-, Immediate-release), By End-user, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points:

Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Product Type (Tablets, Capsules), By Mechanism (Controlled-, Immediate-release), By End-user, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
The demand for patient-centric dosage forms has been increasing with time, making it a pivotal trend in the medical field, as it enhances medication adherence.
To render solid oral drugs more user-friendly, drug sponsors are innovatively transforming drugs into micro or mini tablets and sprinkle capsules.
Furthermore, increasing undertaking of strategic initiatives by key players is also expected to drive U.S. oral solid dosage (OSD) contract manufacturing market growth.

Global Healthcare Leaders Advance Sector Decarbonisation Ahead of COP28

Retrieved on:

수요일, 11월 29, 2023

This is the first time that companies from across the global healthcare sector – including AstraZeneca, GSK, Novo Nordisk, Roche – have come together to pioneer such initiatives in these countries.

Key Points:

This is the first time that companies from across the global healthcare sector – including AstraZeneca, GSK, Novo Nordisk, Roche – have come together to pioneer such initiatives in these countries.
Today’s commitments ahead of COP28, which marks the first global climate conference to have an official focus on health, build on bold action already taken by the group to decarbonise healthcare .
The Working Group aims to accelerate the delivery of sustainable healthcare in China, with broader global impact.
Ahead of COP28, new Task Force members Bupa, Novartis and Reckitt joined the collaboration.

Stem Cell Therapy Contract Manufacturing Market Report 2023-2033 - Advances in Cell Biology and Regenerative Medicine Propels Stem Cell Therapy Market

Retrieved on:

목요일, 12월 14, 2023

Cell biology, Research, Catalent, Organization, Regenerative medicine, AbbVie, Retail, Lonza

DUBLIN, Dec. 14, 2023 /PRNewswire/ -- The "Stem Cell Therapy Contract Manufacturing Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Dec. 14, 2023 /PRNewswire/ -- The "Stem Cell Therapy Contract Manufacturing Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.
In an insightful new research publication, the burgeoning stem cell therapy contract manufacturing market is analyzed in extensive detail, projecting a surpassing of US$2.75 billion in value for the year 2023 alone.
The latest findings highlight the rapid evolution of the stem cell therapy contract manufacturing market, bolstered by advances in cell biology and regenerative medicine.
The report presents granular forecasts spanning numerous market segments including scale of operation, size of contract manufacturer, and stem cell types, among others.

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

Retrieved on:

목요일, 12월 7, 2023

Ophthalmology, Research, Spacecraft, ADC, Partnership, Antibody, Autoimmunity, Fine chemical, Lonza, Synaffix

Building on the core value proposition of Synaffix ADC technology – to enable best-in-class efficacy and tolerability for ADCs – the expanded deal with Innovent focuses on at least one new ADC candidate.

Key Points:

Building on the core value proposition of Synaffix ADC technology – to enable best-in-class efficacy and tolerability for ADCs – the expanded deal with Innovent focuses on at least one new ADC candidate.
Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates.
Dr. Kaijie He, Vice President of Cancer Biology and ADC Research at Innovent, said: "Innovent has progressed one ADC candidate under the initial phase of our collaboration with Synaffix to the clinical development stage.
This expanded deal adds additional novel ADC to our research projects, allowing us to further build on our understanding of ADC research and ADC pipeline development."

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

Retrieved on:

목요일, 12월 7, 2023

ADC, Antibody, Ophthalmology, HKEX, Research, Spacecraft, Partnership, Fine chemical, Lonza

Under the terms of the expanded agreement, Innovent will focus the development of at least one new ADC candidate, building on Synaffix's ADC technology to enable best-in-class efficacy and tolerability for ADCs.

Key Points:

Under the terms of the expanded agreement, Innovent will focus the development of at least one new ADC candidate, building on Synaffix's ADC technology to enable best-in-class efficacy and tolerability for ADCs.
Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates.
Dr. Kaijie He, Vice President of Cancer Biology and ADC research at Innovent, said: "Innovent has progressed one ADC candidate under the initial phase of our collaboration with Synaffix to the clinical development stage.
This expanded deal adds additional novel ADC to our research projects, allowing us to further build on our understanding of ADC research and ADC pipeline development."

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

Retrieved on:

목요일, 12월 7, 2023

Ophthalmology, Research, Spacecraft, ADC, Partnership, Antibody, Autoimmunity, Fine chemical, Lonza, Synaffix

Building on the core value proposition of Synaffix ADC technology – to enable best-in-class efficacy and tolerability for ADCs – the expanded deal with Innovent focuses on at least one new ADC candidate.

Key Points:

Building on the core value proposition of Synaffix ADC technology – to enable best-in-class efficacy and tolerability for ADCs – the expanded deal with Innovent focuses on at least one new ADC candidate.
Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates.
Dr. Kaijie He, Vice President of Cancer Biology and ADC Research at Innovent, said: "Innovent has progressed one ADC candidate under the initial phase of our collaboration with Synaffix to the clinical development stage.
This expanded deal adds additional novel ADC to our research projects, allowing us to further build on our understanding of ADC research and ADC pipeline development."

The TIM Company Appoints Biotech Veteran Dr. Behzad Mahdavi as Transformative CEO and Board Member

Retrieved on:

화요일, 11월 28, 2023

Cell biology, The, Chemistry, Patient, FDA, Automation, MBA, Commercial UAS Modernization Act, Growth, Synthetic biology, Knowledge, Management, Lonza

Dr. Mahdavi is a biotech industry veteran and business leader known for his expertise in developing successful, patient-centric business growth strategies across biopharma.

Key Points:

Dr. Mahdavi is a biotech industry veteran and business leader known for his expertise in developing successful, patient-centric business growth strategies across biopharma.
In addition to his industry leadership roles, Dr. Mahdavi has made significant contributions as a member of multiple Boards of Directors and Advisory Boards.
"In the upcoming period, we will embark on a transformative journey at The TIM Company, embodying our bold vision for the future.
said Dr. Behzad Mahdavi, the newly appointed CEO of The TIM Company.

Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds

Retrieved on:

화요일, 11월 7, 2023

SIX Swiss Exchange, Lonza, CHF, Cryptocurrency, Fine chemical

Basel, Switzerland, 06 November 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 400 million dual-tranche straight-bond issuance in line with its financing plan for 2023.

Key Points:

Basel, Switzerland, 06 November 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 400 million dual-tranche straight-bond issuance in line with its financing plan for 2023.
The bonds have a maturity of 4.5 years and 7.5 years respectively with coupons of 2.250% and 2.600%.
The issuer is Lonza Swiss Finance Ltd, Basel, and the bonds will be guaranteed by Lonza.
Lonza will apply for the listing of the bonds on the SIX Swiss Exchange.

Global 3D Cell Culture (Scaffold Based, Scaffold Free) Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on:

금요일, 10월 6, 2023

The "3D Cell Culture Market Size, Share & Trends Analysis Report By Technology (Scaffold Based, Scaffold Free), By Application (Cancer, Drug Development), By End-use, By Region, And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "3D Cell Culture Market Size, Share & Trends Analysis Report By Technology (Scaffold Based, Scaffold Free), By Application (Cancer, Drug Development), By End-use, By Region, And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
The global 3D cell culture market size is expected to reach USD 3.31 billion by 2030, expanding at 11.04% CAGR from 2023 to 2030.
Tissue engineering has achieved remarkable progress by developing 3D culture models that closely mimic in-vivo conditions, surpassing traditional 2D cell cultures.
These technologies provide precise control over culture conditions, cell organization, and high-efficiency screening, driving the utilization of 3D culture systems.